Former President Joe Biden diagnosed with ‘aggressive’ form of prostate cancer

Former President Joe Biden diagnosed with ‘aggressive’ form of prostate cancer


Former President Joe Biden speaks during the Advocates, Counselors, and Representatives for the Disabled bipartisan conference at the Sofitel Chicago Magnificent Mile on Tuesday, April 15, 2025.

Eileen T. Meslar | Chicago Tribune | Getty Images

Former President Joe Biden has been diagnosed with prostate cancer, his office said Sunday.

Biden was seen last week by doctors after urinary symptoms and a prostate nodule was found. He was diagnosed with prostate cancer on Friday, with the cancer cells having spread to the bone. His office said he has stage 9 cancer.

“While this represents a more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management,” his office said. “The President and his family are reviewing treatment options with his physicians.”

Prostate cancers are given a score called a Gleason score that measures, on a scale of 1 to 10, how the cancerous cells look compared with normal cells. Biden’s score of 9 suggests his cancer is among the most aggressive.

When prostate cancer spreads to other parts of the body, it often spreads to the bones. Metastasized cancer is much harder to treat than localized cancer because it can be hard for drugs to reach all the tumors and completely root out the disease.

However, when prostate cancers need hormones to grow, as in Biden’s case, they can be susceptible to treatment that deprives the tumors of hormones.

The health of Biden, 82, was a dominant concern among voters during his time as president. After a calamitous debate performance in June while seeking reelection, Biden abandoned his bid for a second term. Then-Vice President Kamala Harris became the nominee and lost to Republican Donald Trump, who returned to the White House after a four-year hiatus.

But in recent days, Biden rejected concerns about his age despite reporting in the new book “Original Sin” by Jake Tapper and Alex Thompson that aides had shielded the public from the extent of his decline while serving as president.

In February 2023, Biden had a skin lesion removed from his chest that was a basal cell carcinoma, a common form of skin cancer. And in November 2021, he had a polyp removed from his colon that was a benign, but potentially pre-cancerous lesion.

In 2022, Biden made a “cancer moonshot” one of his administration’s priorities with the goal of halving the cancer death rate over the next 25 years. The initiative was a continuation of his work as vice president to address a disease that had killed his older son, Beau.



Source

CoreWeave beats revenue projections as backlog swells to nearly  billion
World

CoreWeave beats revenue projections as backlog swells to nearly $67 billion

Michael Intrator, Chief Executive Officer of CoreWeave Inc., speaks during an interview with CNBC on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., Sept. 22, 2025. Jeenah Moon | Reuters CoreWeave shares fell as much as 11% in extended trading on Thursday after the artificial intelligence-focused cloud infrastructure provider […]

Read More
Warner Bros. Discovery deems Paramount Skydance offer superior to Netflix, starting 4-day matching clock
World

Warner Bros. Discovery deems Paramount Skydance offer superior to Netflix, starting 4-day matching clock

The Paramount logo is shown on a structure at the Paramount studio lot in Hollywood, Los Angeles, California, U.S., Feb. 26, 2026. Mike Blake | Reuters Warner Bros. Discovery has valued Paramount Skydance‘s latest offer as superior to Netflix, another twist in the ongoing sale process. Netflix will have four business days to make changes […]

Read More
DoorDash has been volatile of late but these analysts tout it as a ‘core holding’ for internet investors
World

DoorDash has been volatile of late but these analysts tout it as a ‘core holding’ for internet investors

DoorDash shares have been volatile of late, but it hasn’t shaken Wall Street’s conviction in growth opportunities for the stock. Shares of the food delivery platform initially tumbled as much as 12% in extended trading on Feb. 18, after DoorDash’s fourth-quarter earnings missed expectations. Its forecast also disappointed as the company warned investments in Deliveroo […]

Read More